William K. Oh Prioritized Precision Oncology Education

The Yale Cancer Center director emphasized clinician training to improve patient access to targeted therapies.

Updated on Sept. 28, 2026 in Cancer

Isometric editorial illustration of a medical lab vial and centrifuge rotor, representing the precision of cancer oncology research. — Yale Cancer Center director William K. Oh is leading new initiatives to train clinicians in precision oncology, aiming to expand access to biomarker testing and targeted therapies. AI Illustration. Upload story photo >

Live Poll

Should insurance coverage requirements for advanced medical testing be expanded to ensure equitable patient access?

In 2026, William K. Oh, director of precision medicine at Yale Cancer Center, led efforts to advance clinician education in precision oncology. These initiatives focused on using tumor boards and webinars to help physicians better utilize biomarker testing for patient care.

Why it matters

Expanding physician expertise in precision medicine is critical to addressing health equity gaps. Without proper training and coverage for advanced testing, new technologies risk leaving patients in underserved populations behind.

Most current germline data originates from patients of European ancestry, which limits the understanding of pathogenic variants. Additionally, state laws mandating coverage for biomarker testing often exclude liquid biopsy or minimal residual disease tools.

The players

William K. Oh

He serves as the director of precision medicine at Yale Cancer Center and is an expert in advancing oncology education.

Yale Cancer Center

This facility is a major research and clinical institution in New Haven that utilizes tumor boards to train physicians in precision medicine.

The details

Clinicians utilize biomarker testing to identify patient eligibility for specific drug candidates and targeted therapies. Yale Cancer Center supports this process by providing ongoing education to both trainees and attending physicians through specialized tumor boards and webinars.

2026: William K. Oh presented these clinical education priorities at the Patient-Centered Oncology Care conference.

The Big Picture

This effort follows the evolution of state laws requiring coverage for biomarker testing, which currently fail to fully support modern diagnostic tools. By focusing on education, Yale aims to bridge the gap between existing insurance mandates and the clinical requirements for liquid biopsies.

Patients may benefit from more clinicians who are trained to order necessary biomarker testing for targeted therapies. However, residents should note that insurance coverage for newer testing methods like liquid biopsies remains inconsistent under current state laws.

The takeaway

Precision medicine requires both physician training and robust insurance coverage to be effective for all patients. Readers should discuss available biomarker testing options with their oncology teams to determine if targeted therapies are appropriate for their specific diagnosis.